BACKGROUND: No accurate estimates of cervical cancer incidence or mortality currently exist in Georgia. Nor are there any data on the population-based prevalence of high-risk (HR) human papillomavirus (HPV) infection, which, in the absence of good-quality screening, is known to correlate with cervical cancer incidence. METHODS: We obtained cervical cell specimens from 1309 women aged 18-59 years from the general population of Tbilisi, and also from 91 locally diagnosed invasive cervical cancers (ICC). DNA of 44 HPV types was tested for using a GP5+/6+-based PCR assay. RESULTS: In the general population (of whom 2% reported a previous Pap smear) HPV prevalence was 13.5% (95% CI: 11.6-15.9), being highest in women aged 25-34 years (18.7%) and falling to between 8.6% and 9.5% for all age groups above 34 years. HR HPV prevalence was 8.6% overall, being 6.8% and 38.9% among women with normal and abnormal cytology, respectively. HPV45 (1.6%) was the most common type in women with normal cytology, whereas HPV16 predominated among women with cervical abnormalities (including 7 of 10 histologically confirmed cervical intraepithelial neoplasia 2/3) and among ICC (57.6%). The next most common types in ICC in Georgia were HPV45 and 18 (13.2 and 11.0%, respectively). CONCLUSIONS: We report a relatively high burden of HPV infection in Tbilisi, Georgia. Improving cervical cancer prevention, through screening and/or HPV vaccination, is an important public health issue in Georgia, where 70% of ICC are theoretically preventable by HPV16/18 vaccines.
BACKGROUND: No accurate estimates of cervical cancer incidence or mortality currently exist in Georgia. Nor are there any data on the population-based prevalence of high-risk (HR) human papillomavirus (HPV) infection, which, in the absence of good-quality screening, is known to correlate with cervical cancer incidence. METHODS: We obtained cervical cell specimens from 1309 women aged 18-59 years from the general population of Tbilisi, and also from 91 locally diagnosed invasive cervical cancers (ICC). DNA of 44 HPV types was tested for using a GP5+/6+-based PCR assay. RESULTS: In the general population (of whom 2% reported a previous Pap smear) HPV prevalence was 13.5% (95% CI: 11.6-15.9), being highest in women aged 25-34 years (18.7%) and falling to between 8.6% and 9.5% for all age groups above 34 years. HR HPV prevalence was 8.6% overall, being 6.8% and 38.9% among women with normal and abnormal cytology, respectively. HPV45 (1.6%) was the most common type in women with normal cytology, whereas HPV16 predominated among women with cervical abnormalities (including 7 of 10 histologically confirmed cervical intraepithelial neoplasia 2/3) and among ICC (57.6%). The next most common types in ICC in Georgia were HPV45 and 18 (13.2 and 11.0%, respectively). CONCLUSIONS: We report a relatively high burden of HPV infection in Tbilisi, Georgia. Improving cervical cancer prevention, through screening and/or HPV vaccination, is an important public health issue in Georgia, where 70% of ICC are theoretically preventable by HPV16/18 vaccines.
Authors: Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford Journal: J Virol Date: 2014-02-05 Impact factor: 5.103
Authors: Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Zigui Chen; Robert D Burk; Hugo De Vuyst; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford Journal: Virology Date: 2013-11-12 Impact factor: 3.616
Authors: Cristiana Banila; Attila T Lorincz; Dorota Scibior-Bentkowska; Gary M Clifford; Birhanu Kumbi; Dereje Beyene; Cosette M Wheeler; Kate Cuschieri; Jack Cuzick; Belinda Nedjai Journal: Int J Cancer Date: 2021-10-11 Impact factor: 7.396
Authors: Erik Bernard; Margarita Pons-Salort; Michel Favre; Isabelle Heard; Elisabeth Delarocque-Astagneau; Didier Guillemot; Anne C M Thiébaut Journal: BMC Infect Dis Date: 2013-08-13 Impact factor: 3.090
Authors: Andréia Rodrigues Gonçalves Ayres; Gulnar Azevedo E Silva; Maria Teresa Bustamante Teixeira; Kristiane de Castro Dias Duque; Maria Lúcia Salim Miranda Machado; Carmen Justina Gamarra; José Eduardo Levi Journal: Rev Saude Publica Date: 2017-10-05 Impact factor: 2.106